A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...
Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the ...
Investor's Business Daily on MSN
Upstream Bio crashes after asthma drug succeeds — with the wrong dose
Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent ...
The clinical-stage biotechnology company said the Phase 2 Valiant clinical trial, evaluating verekitug in adults with severe asthma, showed that verekitug reduced asthma attacks and improved lung ...
Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq. Upstream had previously expected to sell 12 ...
Upstream for Web was developed as a natural extension of the existing iOS and Android apps that offer a community platform that already enjoys great success at connecting professionals that might ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results